Bicycle Therapeutics plc (BCYC) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 48.1 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BCYC currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.83) and Max Pain ($4.01) forces dealer call-delta covering toward $8.52.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Bicycle Therapeutics plc (BCYC) slipped -1.55% to $3.82, trading at 10% of its 52-week range ($3.33 – $8.11). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
CAMBRIDGE, England & BOSTON, October 29, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycl
Bicycle Therapeutics (NASDAQ:BCYC) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.48) by 68.75 percent. This is a 82.35 percent increase over losses of $(0.85) per share
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +105.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BCYC today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BCYC. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Bicycle Therapeutics plc (BCYC) ranks #996 by composite RQD confidence (24/100, grade E) and #534 by equity capitalization ($267.4M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with BCYC at 24/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BCYC
ACTIVE
Bicycle Therapeutics plc | E | 24/100 | — | — | -35.0% | -1.55% | $267.4M | Benchmark Subject |
| QTTB Q32 Bio Inc. | C- | 61/100 | 8.9x | — | 85.0% | -2.10% | $264.1M | /qttb-vs-bcyc → |
| AMRN Amarin Corporation plc | D- | 43/100 | — | 56.6% | -12.2% | -0.08% | $262.8M | /amrn-vs-bcyc → |
| BIOA BioAge Labs Inc. | D | 44/100 | — | — | -35.0% | 0.00% | $272.6M | /bioa-vs-bcyc → |
| ABEO Abeona Therapeutics Inc. | D- | 39/100 | — | 73.7% | -35.0% | +0.22% | $260.8M | /abeo-vs-bcyc → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bicycle Therapeutics plc (BCYC) reported GAAP revenue of $72.6M (+105.8% vs. FY2024 revenue of $35.3M , and +169.1% cumulative change since FY2023) , GAAP net income of -$219.0M, operating cash flow of -$249.7M, and free cash flow of -$252.0M (-51.9% YoY). On the balance sheet, BCYC closed FY2025 with $717.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $72.6M | -$219.0M | -$249.7M | -$252.0M | $717.6M | — |
| FY2024 (FY) | 2024-12-31 | $35.3M | -$169.0M | -$164.7M | -$166.0M | $956.9M | — |
| FY2023 (FY) | 2023-12-31 | $27.0M | -$180.7M | -$60.6M | -$60.6M | — | — |
As of 2026-11-01, Bicycle Therapeutics plc (NASDAQ: BCYC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $3.82 (-1.55% 1D, market cap $267.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCYC ranks #996 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCYC carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, QTTB (Q32 Bio Inc.) holds a C- grade (61/100 RQD, P/E 8.9x, ROIC 85.0%, cap $264.1M) and AMRN (Amarin Corporation plc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).
Per BCYC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001761612), Bicycle Therapeutics plc generated $72.6M in revenue (+105.8% YoY), -$219.0M in net income, and -$252.0M in free cash flow against $717.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BCYC last traded at $3.82 (-1.55% on volume of 598,183 shares), positioning the stock -0.26% below its 50-day simple moving average ($3.83) and -16.23% below its 200-day simple moving average ($4.56). Across its 52-week range of $3.33 to $8.11, BCYC sits at the 10.3% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.34 to $4.30).
Why BCYC Stock slipped -1.55% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.